Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.